News | October 30, 2025
Lilly to invest $1.2 billion+ to boost oral medicine manufacturing capacity in US
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Subscribe To Our Newsletter & Stay Updated
